Shin Poong Pharm.Co.,Ltd.

KSE 019170.KS

Shin Poong Pharm.Co.,Ltd. Gross Profit for the year ending December 31, 2023: USD 61.65 M

Shin Poong Pharm.Co.,Ltd. Gross Profit is USD 61.65 M for the year ending December 31, 2023, a 0.09% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Shin Poong Pharm.Co.,Ltd. Gross Profit for the year ending December 31, 2022 was USD 61.60 M, a -4.90% change year over year.
Shin Poong Pharm.Co.,Ltd. Gross Profit for the year ending December 31, 2021 was USD 64.77 M, a -7.80% change year over year.
Shin Poong Pharm.Co.,Ltd. Gross Profit for the year ending December 31, 2020 was USD 70.25 M, a 6.98% change year over year.
Shin Poong Pharm.Co.,Ltd. Gross Profit for the year ending December 31, 2019 was USD 65.67 M, a -3.20% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

KSE: 019170.KS

Shin Poong Pharm.Co.,Ltd.

CEO	Mr. Jei-Man Ryu
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	161, Yeoksam-ro
Employees	828
Sector	Health Care
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies

Description

Shin Poong Pharm.Co.,Ltd. manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products. It also provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; and over the counter products. The company also exports its products to approximately 50 countries. Shin Poong Pharm.Co.,Ltd. was founded in 1962 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years